🔎 Trials Near Me

Home › Ewing Sarcoma › Massachusetts

Pag-aaral pangklinika para sa Ewing Sarcoma sa Massachusetts

6 pag-aaral para sa Ewing Sarcoma ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 2 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07297979

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Dana-Farber Cancer Institute ( Site 1013), Boston
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103

Lurbinectedin in FET-Fused Tumors

  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 10 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05918640

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

  • Mass General Brigham Cancer Institute, Boston
  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 16 pataas · Lahat ng kasarian · Na-update Hun 2, 2026 · NCT07197554

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Nagre-recruitPhase 1/2
Edad 12 hanggang 49 · Lahat ng kasarian · Na-update Peb 19, 2026 · NCT06709495

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.